These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 35959620)
41. Best Practice Approach to Successful Conversion of Fosaprepitant to Aprepitant IV in a Large Multisite Community Oncology Infusion Center: A Retrospective Analysis. Burns D; Kula J; Marshall S; Ashworth E; Ornelas M Adv Ther; 2020 Jul; 37(7):3265-3277. PubMed ID: 32447650 [TBL] [Abstract][Full Text] [Related]
42. The neurokinin1 receptor antagonist aprepitant as an antiemetic for moderately emetogenic chemotherapy. Warr D Expert Opin Pharmacother; 2006 Aug; 7(12):1653-8. PubMed ID: 16872268 [TBL] [Abstract][Full Text] [Related]
43. Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis. Zhang Y; Yang Y; Zhang Z; Fang W; Kang S; Luo Y; Sheng J; Zhan J; Hong S; Huang Y; Zhou N; Zhao H; Zhang L J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27795228 [TBL] [Abstract][Full Text] [Related]
44. Varicella Zoster Virus Induces Nuclear Translocation of the Neurokinin-1 Receptor, Promoting Lamellipodia Formation and Viral Spread in Spinal Astrocytes. Bubak AN; Como CN; Blackmon AM; Frietze S; Mescher T; Jones D; Cohrs RJ; Paucek P; Baird NL; Nagel MA J Infect Dis; 2018 Sep; 218(8):1324-1335. PubMed ID: 29788447 [TBL] [Abstract][Full Text] [Related]
45. NK-1 receptor antagonists: a new generation of anticancer drugs. Munoz M; Covenas R Mini Rev Med Chem; 2012 Jun; 12(7):593-9. PubMed ID: 22512565 [TBL] [Abstract][Full Text] [Related]
46. The involvement of the substance P/neurokinin 1 receptor system in viral infection: focus on the gp120 fusion protein and homologous dipeptide domains. Muñoz M; Coveñas R; Kramer M Acta Virol; 2019; 63(3):253-260. PubMed ID: 31507190 [TBL] [Abstract][Full Text] [Related]
47. Therapeutic and preventive antiemetic effect of aprepitant in Japanese patients with thoracic malignancies who truly need it. Ito S; Tsukiyama I; Ando M; Katakami M; Hamanaka R; Kosaka K; Matsubara A; Nishimura M; Tanaka H; Asai N; Yokoe N; Takahashi A; Baba K; Matsuura K; Yamaguchi E; Kubo A Support Care Cancer; 2015 Apr; 23(4):905-12. PubMed ID: 25223352 [TBL] [Abstract][Full Text] [Related]
48. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo. Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605 [TBL] [Abstract][Full Text] [Related]
49. Substance P and Neurokinin-1 Receptor System in Thyroid Cancer: Potential Targets for New Molecular Therapies. Isorna I; González-Moles MÁ; Muñoz M; Esteban F J Clin Med; 2023 Oct; 12(19):. PubMed ID: 37835053 [TBL] [Abstract][Full Text] [Related]
50. The In Vitro Pro-inflammatory Functions of the SP/NK1R System in Prostate Cancer: a Focus on Nuclear Factor-Kappa B (NF-κB) and Its Pro-inflammatory Target Genes. Ebrahimi S; Erfani B; Alalikhan A; Ghorbani H; Farzadnia M; Afshari AR; Mashkani B; Hashemy SI Appl Biochem Biotechnol; 2023 Dec; 195(12):7796-7807. PubMed ID: 37093533 [TBL] [Abstract][Full Text] [Related]
51. Neurokinin-1-receptor antagonists: a new approach in antiemetic therapy. Jordan K Onkologie; 2006 Feb; 29(1-2):39-43. PubMed ID: 16514255 [TBL] [Abstract][Full Text] [Related]
53. Aprepitant in the prevention of vomiting induced by moderately and highly emetogenic chemotherapy. Wang SY; Yang ZJ; Zhang Z; Zhang H Asian Pac J Cancer Prev; 2014; 15(23):10045-51. PubMed ID: 25556423 [TBL] [Abstract][Full Text] [Related]
54. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F; Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346 [TBL] [Abstract][Full Text] [Related]
55. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859 [TBL] [Abstract][Full Text] [Related]
56. Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin. Jahn F; Riesner A; Jahn P; Sieker F; Vordermark D; Jordan K Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1101-1107. PubMed ID: 26059352 [TBL] [Abstract][Full Text] [Related]
57. Neurokinin-1 Receptor (NK-1R) Antagonists: Potential Targets in the Treatment of Glioblastoma Multiforme. Afshari AR; Motamed-Sanaye A; Sabri H; Soltani A; Karkon-Shayan S; Radvar S; Javid H; Mollazadeh H; Sathyapalan T; Sahebkar A Curr Med Chem; 2021; 28(24):4877-4892. PubMed ID: 33441062 [TBL] [Abstract][Full Text] [Related]
58. Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Dando TM; Perry CM Drugs; 2004; 64(7):777-94. PubMed ID: 15025555 [TBL] [Abstract][Full Text] [Related]
59. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting. Navari RM Expert Rev Anticancer Ther; 2015; 15(10):1127-33. PubMed ID: 26366937 [TBL] [Abstract][Full Text] [Related]
60. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Bergström M; Hargreaves RJ; Burns HD; Goldberg MR; Sciberras D; Reines SA; Petty KJ; Ogren M; Antoni G; Långström B; Eskola O; Scheinin M; Solin O; Majumdar AK; Constanzer ML; Battisti WP; Bradstreet TE; Gargano C; Hietala J Biol Psychiatry; 2004 May; 55(10):1007-12. PubMed ID: 15121485 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]